Dexcom logo

Dexcom

0 followers

DXCM

Performance

About Dexcom

Dexcom is a global medical device company specializing in continuous glucose monitoring (CGM) technology for diabetes management. It develops and markets CGM systems that provide real-time glucose readings and data to phones or receivers, enabling users to monitor glucose levels and make informed health decisions. The company has a long history in glucose biosensing and supports an ecosystem of connected partners, with products like Dexcom G7 and Stelo Glucose Biosensor, and operates worldwide from its base in San Diego, California. Since its founding in 1999, Dexcom has focused on improving diabetes care by delivering accurate, non-invasive or minimally invasive glucose monitoring solutions.

Recent News

New Study Published Evaluating PharmaSens All-in-One Insulin Patch Pump

Health Recovery Solutions (HRS) Acquires Rimidi for Chronic Care Management and RPM Integration

Dexcom Unveils Next-Generation G8 CGM for Real-Time Glucose Monitoring

FDA Approves Automated Insulin Delivery System for Pregnancy

GLP-1 Microdosing May Provide More ‘Tailored Approach to Care’

Stocks Making the Biggest Moves Midday: Moderna, Instacart, Rivian Automotive, DraftKings, Coinbase & More

Elliott Investment Management Takes Stake in Dexcom, Secures Two Board Seats

Some Implied Moves for Earnings Next Week(Apr. 27th – May 1st) – 726 Companies Reporting

Apple Watch Glucose Monitoring Gets Major Breakthrough

Dexcom Unveils G8 CGM, a 50% Smaller Sensor Set for 2027 Launch

GlucoTrack Shares Jump 34% as FDA IDE Submission Looms for Implantable Glucose Monitor

Senseonics Rolls Out Eversense 365, First One‑Year CGM, Across Europe

Combining Data Can Identify High-Risk Cohorts for SDOH Initiatives

Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins

Alphabet Boosts Portfolio Value by $1.5 B, Adds CME Group as Top Holding

Google Unveils Screenless Fitbit Air, New Google Health App

Dexcom Seeks Expanded Medicare Coverage of CGMs for Type 2 Diabetes

US Stocks Today | Big Tech Stocks Lose Billions as AI Spending Fears Hit Valuations

Multiple CGM Sensors May Be Used with Automated Insulin Delivery

Sell in May and Go Away—Starting With These 3 Stocks

AI Nutrition Tracking Stinks

Market Quote of the Day by Sir John Templeton | “The Time of Maximum Pessimism Is the Best Time to Buy”

Recent Deals

No recent deals for this company.